Retro Biosciences

Develops therapeutics targeting aging mechanisms

Redwood City, California, United States

About Retro Biosciences

Retro Biosciences focuses on extending healthy human lifespan by ten years through the development of therapeutics that target the cellular mechanisms of aging. The company addresses the root causes of age-related diseases, which are responsible for a significant portion of healthcare costs. Its product development is organized into three main programs: cellular reprogramming, plasma-inspired therapeutics, and autophagy, each at different stages of progress. Retro Biosciences utilizes advanced technologies like single-cell multi-omics and computational biology to enhance its research and development efforts. Unlike many competitors, Retro Biosciences aims to prevent multiple diseases by focusing on aging itself rather than treating individual conditions. The company's goal is to reduce healthcare expenses associated with aging and improve the quality of life for individuals as they age.

Redwood City, CaliforniaHeadquarters
2021Year Founded
$175.1MTotal Funding
EARLY_VCCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Parental Leave
Professional Development Budget

Risks

Ethical concerns about life extension technologies could lead to regulatory challenges.
Increased competition from companies like Calico and Unity Biotechnology poses a threat.
Reliance on evolving technologies like single-cell multi-omics may pose scalability challenges.

Differentiation

Retro Biosciences focuses on cellular reprogramming, autophagy, and plasma-inspired therapeutics.
The company aims to extend healthy human lifespan by ten years.
Retro Biosciences employs advanced technologies like single-cell multi-omics and computational biology.

Upsides

Retro Biosciences secured $180 million in initial funding for research and development.
The $85 million partnership with Multiply Labs enhances cell therapy manufacturing capabilities.
Growing interest in epigenetic reprogramming and plasma-inspired therapeutics supports Retro's mission.

Funding

Total raised$175.09 M
Latest valuation$900.00 M
StageEARLY_VC
EARLY VC
3/31/2022
$180
$900.00 M